Saikosaponin D

Catalog No.S5454 Batch:S545402

Print

Technical Data

Formula

C42H68O13
Molecular Weight 780.98 CAS No. 20874-52-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (128.04 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is a type of Saponin derivative, which is a component extracted from Bupleurum falactum. Saikosaponin D has anti-cancer activities.
Targets
SERCA [1]
In vitro Saikosaponin D is a novel autophagic inducer that induces autophagy in various types of cancer cells through the formation of autophagosomes as measured by GFP-LC3 puncta formation. Saikosaponin D increases cytosolic calciumlevel via direct inhibition of sarcoplasmic/endoplasmic reticulum Ca2+ATPase pump, leading to autophagy induction through the activation of the Ca2+/calmodulin-dependent kinase kinase-AMP-activated protein kinase-mammalian target of rapamycin pathway. Its treatment causes the disruption of calcium homeostasis, which induces endoplasmic reticulum stress as well as the unfolded protein responses pathway[1]. Ssd can exhibit anti-cancer activities, which is mediated by the induction of apoptosis and autophagic cell death regardless of p53 status. Low dose Ssd is capable of sensitizing chremosensitive or chemoresistant lung and cervical cancer or hepatoma cells to anti-cancer drug- or radiation-induced apoptosis. Ssd also down-regulates PPM1D content, leading to the activation of Chk1, phosphorylation of Cdc25c and Cdk1, and subsequent G2/M arrest and apoptosis[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HeLa and MCF-7 cells

  • Concentrations

    10 μM

  • Incubation Time

    1, 4, 8 and 24 h

  • Method

    HeLa and MCF-7 cells were treated with Ssd (10 μM) for the indicated time, whereas rapamycin (100 nM) and thapsigargin (1 μM) were used as positive control. Cell lysates were harvested and analyzed by western blot for ER stress markers.
Animal Study:

[3]
  • Animal Models

    Pathogen-free, BALB/C male mice aged 6-8 weeks old

  • Dosages

    1, 5, 10 and 20 mg/kg

  • Administration

    intramuscularly

Selleck's Saikosaponin D has been cited by 1 publication

Repurposing FDA-Approved Drugs for Temozolomide-Resistant IDH1 Mutant Glioma Using High-Throughput Miniaturized Screening on Droplet Microarray Chip [ Adv Healthc Mater, 2023, e2300591.] PubMed: 37162029

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.